ReviewSynthetic and systems biotechnology2026
Programmable spatiotemporal control of CRISPR-Cas12a: Engineering precision for next-generation gene editing and diagnostics.
Review in Synthetic and systems biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR-Cas12a has emerged as a versatile alternative to Cas9, offering distinct advantages, such as recognition of thymine-rich protospacer adjacent motifs, generation of staggered 5' DNA breaks, simplified guide RNA architecture, and collateral (trans) single-stranded DNA cleavage. These features have enabled applications ranging from gene regulation to ultrasensitive nucleic-acid detection. However, Cas12a is typically activated immediately upon target engagement and may lack intrinsic mechanisms for restricting activity in time or space, which can increase off-target effects, systemic exposure, and loss of tissue specificity in certain contexts. Consequently, strategies that enable precise spatiotemporal control of Cas12a activity are increasingly important. Recent advances, including photocaged repeat-recognition sequence-based designs, split-crRNA architectures, chemically inducible systems, and kinetic optimization approaches, provide effective means to modulate Cas12a activation with improved precision. In diagnostic settings, temporal gating enhances signal fidelity by reducing background and false-positive readouts, while in therapeutic applications, controlled activation may enable tissue-restricted editing and safer, reversible gene regulation. This review summarizes current strategies for programmable spatiotemporal control of Cas12a, integrating mechanistic insights with emerging translational considerations, and outlines remaining challenges and opportunities for advancing safe and precise genome engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.